Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals
DC
First Claim
Patent Images
1. A crystalline form of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole, wherein said crystalline form has a powder X-ray diffraction pattern comprising a peak at diffraction angle (2θ
- ) of 6.0±
0.1 and further comprising at least one peak at diffraction angle (2θ
) selected from 11.5±
0.1, 21.0±
0.1 and 26.9±
0.1.
1 Assignment
Litigations
0 Petitions
Accused Products
Abstract
The present invention relates to crystalline polymorphic and amorphous form of 6-[2-(methylcarbamoyl)phenyl sulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one polymorphic form and to the therapeutic or prophylactic use of such polymorphic forms and compositions.
20 Citations
6 Claims
-
1. A crystalline form of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole, wherein said crystalline form has a powder X-ray diffraction pattern comprising a peak at diffraction angle (2θ
- ) of 6.0±
0.1 and further comprising at least one peak at diffraction angle (2θ
) selected from 11.5±
0.1, 21.0±
0.1 and 26.9±
0.1.
- ) of 6.0±
-
2. A crystalline form of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole, wherein said crystalline form has a powder X-ray diffraction pattern comprising a peak at diffraction angle (2θ
- ) of 6.0±
0.1, 11.9±
0.1 and 22.8±
0.1.
- ) of 6.0±
-
3. A crystalline form of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole, wherein said crystalline form has a powder X-ray diffraction pattern comprising a peak at diffraction angle (2θ
- ) of 11.9±
0.1 and 21.0±
0.1, and further comprising at least one peak at diffraction angle (2θ
) selected from 22.8±
0.1, 23.1±
0.1 and 26.9±
0.1.
- ) of 11.9±
-
4. A crystalline form of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole, wherein said crystalline form has a powder X-ray diffraction pattern comprising a peak at diffraction angle (2θ
- ) of 11.5±
0.1 and 15.6±
0.1, and further comprising at least one peak at diffraction angle (2θ
) selected from 16.2±
0.1 and 16.5±
0.1.
- ) of 11.5±
-
5. A crystalline form of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole, wherein said crystalline form has a solid state NMR spectrum comprising 13C chemical shifts at 150.1±
- 0.2, 136.6±
0.2, 135±
0.2, 116.9±
0.2 and 27.5±
0.2 ppm.
- 0.2, 136.6±
-
6. A crystalline form of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole, wherein said crystalline form has a powder X-ray diffraction pattern comprising a peak at diffraction angle (2θ
- ) of 6.0±
0.1 and 11.5±
0.1 and wherein said crystalline form has a solid state NMR spectrum comprising 13C chemical shifts at 150.1±
0.2 and 27.5±
0.2 ppm.
- ) of 6.0±
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
Litigation Data
-
Current AssigneePfizer Inc.
-
Original AssigneePfizer Inc.
-
InventorsCampeta, Anthony Michael, Chekal, Brian Patrick, Singer, Robert Alan
-
Primary Examiner(s)Morris, Patricia L
-
Application NumberUS12/594,575Publication NumberTime in Patent Office2,317 DaysField of Search546/275.7, 514/338US Class Current514/338CPC Class CodesA61P 35/00 Antineoplastic agentsA61P 35/02 specific for leukemiaC07D 401/06 linked by a carbon chain co...
